fenofibrate and pravastatin

fenofibrate has been researched along with pravastatin in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (16.95)	18.2507
2000's	25 (42.37)	29.6817
2010's	24 (40.68)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Fent, K; Popovic, M; Smital, T; Zaja, R	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Bouhour, JB; Chevallier, JC; Le Marec, H; Raimondeau, J	1
Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R	1
Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D	1
Bambauer, R; Müller, UA; Schiel, R	1
Durrington, P	1
Adkins, JC; Faulds, D	1
Alonso-Galicia, M; Roman, RJ; Wilson, TW	1
Ellen, RL; McPherson, R	1
Sinzinger, H	1
Bartek, J; Růzicka, V; Stejskal, D	1
Achari, R; Gustavson, LE; Gutterman, C; Pan, WJ; Rieser, MJ; Wallin, BA; Ye, X	1
Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB	1
Caroli-Bosc, C; Caroli-Bosc, FX; Delabre, B; Delmont, JP; Demarquay, JF; Le Gall, P; Montet, JC; Pugliese, P; Rampal, P	1
Galli, C; Pazzucconi, F; Risé, P; Sirtori, CR	1
Balkau, B; Chesnier, MC; Eschwège, E; Maison, P; Mennen, L; Sapinho, D; Sigalas, J	1
Bourgeois, J; Després, JP; Dzavik, V; Laperrière, L; Lemieux, I; Tremblay, G	1
Császár, A; Márk, L	1
Ducobu, J; Salomon, H; VanHaelst, L	1
Barouki, R; Gouédard, C; Koum-Besson, N; Morel, Y	1
Betz, W; Devroey, D; Duquet, W; Velkeniers, B	1
Aller, R; Bachiller, P; de Luis, DA; Eiros Bouza, J; Izaola, O	1
Romaniv, S; Vecka, M; Zák, A; Zeman, M	1
Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S	1
Achari, R; Chira, TO; Esslinger, HU; Gustavson, LE; Koehne-Voss, S; Schweitzer, SM; Yannicelli, HD	1
Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M	1
Komaroff, AL	1
Adachi, M; Hayashi, T; Hirano, T; Ito, Y; Mori, Y; Nagashima, M; Shiraishi, Y; Tokuno, A; Yamamoto, T	1
Cariou, B; Costet, P; Jarnoux, AL; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Nguyen, P; Ouguerram, K; Zaïr, Y	1
Cahay, B; Klinkenberg, R; Mertens, B; Streel, B	1
Dimitri, E; Landry, P; Légaré, N; Tessier, S	1
Bryniarski, L; Ducobu, J; Farnier, M	2
Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A	2
Bryniarski, L; Császár, A; De Niet, S; Ducobu, J; Farnier, M; Marcereuil, D; Retterstøl, K; Steinmetz, A; Vanderbist, F	1
Farnier, M	1
Díaz Rodríguez, Á	1
Flores-Le Roux, JA; Pedro-Botet, J	1
Mantilla, T	1
Hernández Mijares, A	1
Núñez-Cortés, JM	1
Pintó, X	1
Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L	1
González, DF	1
Abounassif, MA; Alanazi, AM; Hefnawy, MM; Mohamed, MS; Mostafa, GA	1
Florence, E; Kenyon, C; Leys, J; Suttels, V; Van den Ende, J; Vekemans, M; Vlieghe, E	1
Cornejo-Uixeda, S; Escoin-Pérez, C; Hernandez-Lorente, E	1

Reviews

8 review(s) available for fenofibrate and pravastatin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Statins and fibrates in the management of diabetic dyslipidemia. Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:7 Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin	1997
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 1997, Volume: 54, Issue:4 Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin	1997
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides	1998
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis]. Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38 Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis	1998
[Antilipemic agents in combined therapy]. Orvosi hetilap, 2002, Aug-25, Volume: 143, Issue:34 Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6	2002
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:5 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Pravastatin; Risk Factors; Triglycerides	2012
[Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors	2014

Trials

15 trial(s) available for fenofibrate and pravastatin

Article	Year
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. The International journal of artificial organs, 1995, Volume: 18, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life	1995
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)]. Vnitrni lekarstvi, 1998, Volume: 44, Issue:10 Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Pravastatin; Proteins; Simvastatin	1998
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. Journal of clinical pharmacology, 2000, Volume: 40, Issue:3 Topics: Adult; Anticholesteremic Agents; Biological Availability; Cross-Over Studies; Drug Antagonism; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Pravastatin	2000
A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis, 2002, Volume: 162, Issue:2 Topics: Adult; Drug Administration Schedule; Fasting; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lipoproteins, LDL; Particle Size; Pravastatin; Triglycerides	2002
Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia. Journal of cardiovascular pharmacology, 2003, Volume: 41, Issue:1 Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Treatment Outcome	2003
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]. Casopis lekaru ceskych, 2003, Volume: 142, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin	2003
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides	2005
The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. Journal of clinical pharmacology, 2005, Volume: 45, Issue:8 Topics: Adult; Anticholesteremic Agents; Area Under Curve; Drug Interactions; Female; Fenofibrate; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isomerism; Male; Metabolic Clearance Rate; Middle Aged; Pravastatin	2005
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS research and human retroviruses, 2005, Volume: 21, Issue:9 Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Treatment Outcome	2005
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination]. Casopis lekaru ceskych, 2005, Volume: 144, Issue:11 Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation Mediators; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Single-Blind Method	2005
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. The American journal of cardiology, 2010, Sep-15, Volume: 106, Issue:6 Topics: Aged; Apolipoproteins; Belgium; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Poland; Pravastatin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Triglycerides	2010
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clinical therapeutics, 2011, Volume: 33, Issue:1 Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin	2011
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Current medical research and opinion, 2011, Volume: 27, Issue:11 Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides	2011
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diabetes & vascular disease research, 2012, Volume: 9, Issue:3 Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome	2012
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. Journal of the International AIDS Society, 2014, Volume: 17 Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome	2014

Other Studies

36 other study(ies) available for fenofibrate and pravastatin

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide. The Journal of biological chemistry, 2013, Nov-22, Volume: 288, Issue:47 Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins	2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
[Biological myolysis during combined fenofibrate-pravastatin therapy]. Presse medicale (Paris, France : 1983), 1992, Apr-11, Volume: 21, Issue:14 Topics: Angina Pectoris; Creatine Kinase; Drug Therapy, Combination; Fenofibrate; Humans; Male; Middle Aged; Pravastatin; Rhabdomyolysis	1992
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. British heart journal, 1995, Volume: 74, Issue:1 Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin	1995
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin	1993
Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:1 Pt 2 Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, Sodium-Restricted; Enzyme Induction; Female; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Kidney; Kidney Glomerulus; Male; Mixed Function Oxygenases; Pravastatin; Proteinuria; Rats; Rats, Inbred Strains; Sodium, Dietary; Triglycerides; Weight Gain	1998
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology, 2000, Volume: 94, Issue:2 Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin	2000
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Digestive diseases and sciences, 2001, Volume: 46, Issue:3 Topics: Anticholesteremic Agents; Cholelithiasis; Double-Blind Method; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pregnancy; Risk Factors; Simvastatin	2001
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:2 Topics: Anticholesteremic Agents; Arachidonic Acid; Cholesterol; Cholesterol, LDL; Diet, Reducing; Fatty Acids; Female; Fenofibrate; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides	2001
A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis, 2002, Volume: 160, Issue:1 Topics: Adult; Body Mass Index; Cohort Studies; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Sex Factors; Treatment Outcome	2002
Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molecular pharmacology, 2003, Volume: 63, Issue:4 Topics: Aryldialkylphosphatase; Carboxylic Ester Hydrolases; DNA; Esterases; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Gene Expression Regulation, Enzymologic; Humans; Hypolipidemic Agents; Indoles; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Tumor Cells, Cultured	2003
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta cardiologica, 2003, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies	2003
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report. Nutrition (Burbank, Los Angeles County, Calif.), 2003, Volume: 19, Issue:10 Topics: Adult; Anticholesteremic Agents; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pravastatin; Treatment Outcome	2003
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
By the way, doctor. I take Pravachol to control my cholesterol, and because of high triglycerides, my doctor wants to add TriCor. But my pharmacist warns against taking both medications. If I don't take TriCor, are there alternatives? Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Drug Interactions; Fenofibrate; Humans; Hypolipidemic Agents; Liver; Pravastatin; Rhabdomyolysis	2005
The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. Journal of atherosclerosis and thrombosis, 2007, Volume: 14, Issue:3 Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides	2007
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. The Journal of biological chemistry, 2008, Apr-11, Volume: 283, Issue:15 Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hyperlipoproteinemia Type II; Lipid Metabolism; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Pravastatin; Promoter Regions, Genetic; Proprotein Convertase 5; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Serine Endopeptidases; Sulfonamides; Up-Regulation	2008
An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. Journal of chromatography. A, 2008, May-02, Volume: 1189, Issue:1-2 Topics: Chromatography, Liquid; Fenofibrate; Humans; Molecular Structure; Pravastatin; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry	2008
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides	2008
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clinical drug investigation, 2012, Apr-01, Volume: 32, Issue:4 Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Databases, Factual; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Time Factors	2012
[The fixed combination of pravastatin and fenofibrate: what can it provide?]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Pravastatin; Risk Factors	2014
[Efficacy studies]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors	2014
[Achievement of therapeutic objectives]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Pravastatin; Risk Factors	2014
[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors	2014
[Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations]. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, 2014, Volume: 26 Suppl 1 Topics: Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors	2014
[Treatment of older patients with dyslipidemia]. Semergen, 2014, Volume: 40 Suppl 1 Topics: Age Factors; Aged; Atherosclerosis; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Pravastatin; Quality of Life	2014
High-performance liquid chromatography and derivative spectrophotometry for simultaneous determination of pravastatin and fenofibrate in the dosage form. Acta pharmaceutica (Zagreb, Croatia), 2014, Volume: 64, Issue:4 Topics: Calibration; Chromatography, High Pressure Liquid; Drug Combinations; Fenofibrate; Pravastatin; Spectrophotometry, Ultraviolet	2014
A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. Journal of medical case reports, 2015, Sep-08, Volume: 9 Topics: Acute Kidney Injury; Aged; Anti-HIV Agents; Anticholesteremic Agents; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Fenofibrate; HIV Infections; Humans; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis	2015
Capecitabine-induced pancreatitits. Medicina clinica, 2018, 06-08, Volume: 150, Issue:11 Topics: Abdomen, Acute; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Oxaliplatin; Pancreatitis; Pravastatin; Sigmoid Neoplasms	2018